← Back to all trials
Recruiting
NCT06346600
A Long-term Follow-up Study to Evaluate SKG0106 in the Treatment of Patients With nAMD
Conditions: Neovascular (Wet) Age-related Macular Degeneration
Sex: All
Ages: 50 Years – N/A
Healthy volunteers: No
Enrollment: 83
Sponsor: Skyline Therapeutics
Location: Ophthalmic Consultants of Boston Boston Massachusetts
Summary
This is a Prospective, Non-interventional, Multicenter, Long-term Follow-up Study to Evaluate SKG0106 in the Treatment of Patients with Neovascular (Wet) Age-related Macular Degeneration (nAMD). All subject who completed the parent clinical study (NCT06213038 and NCT05986864) will undergo safety and efficacy assessments up to 5 years post study drug injection.
Eligibility Criteria
Inclusion Criteria:
Subjects who only meet all of the following criteria are eligible for this study:
* nAMD subjects who have been enrolled in the SKG0106-related study and received SKG0106 injection;
* Subjects who voluntarily sign an informed consent form (ICF) and comply with the protocol to complete the study
Exclusion Criteria:
* Subjects who are judged by the investigator unsuitable for this study
Source: ClinicalTrials.gov (NCT06346600). StuddyBuddy aggregates publicly available trial information.
